Zinc Acne Randomized Trial: What the Evidence Says

Quick Answer

Zinc Acne Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Several factors contribute to the pathogenesis of acne, such as bacterial proliferation of Cutibacterium (C.) acnes, increased sebum secretion, altered follicular keratinization, and hyperandrogenism. [Tommasino Nello (2026); evidence level 4]
• In fact, acne is associated with low self-esteem, embarrassment, social anxiety, and isolation. [Tommasino Nello (2026); evidence level 4]
• Acne, a chronic inflammatory skin disorder, and its sequelae of post-inflammatory hyperpigmentation (PIH) and scarring are both associated with a negative impact on sufferers' quality of life. [Troielli Patricia (2026); evidence level 4]
• Future research should also address structural barriers to evidence generation in Latin America, including heterogeneous healthcare systems, restricted access to dermatologic care, and clinical trials in some areas. [Troielli Patricia (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For zinc acne randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Tommasino Nello (2026). Beyond Isotretinoin: A Narrative Review of Emerging Systemic Therapies for Moderate‐to‐Severe Acne. DOI: 10.1111/jocd.70812. PMCID: PMC13037353. PMID: 41914642. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13037353/
• Troielli Patricia (2026). Integrating Dermocosmetics Into Acne Care in Latin America. DOI: 10.1111/jocd.70776. PMCID: PMC12951007. PMID: 41766326. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12951007/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.